Patients with advanced NSCLC have traditionally been treated with platinum-based two-drug combination chemotherapy in patients with an appropriate performance status. An increase in understanding about the pathogenesis and molecular biology of NSCLC has enabled the more recent development of targeted agents that have changed management paradigms.
Navigating the NSCLC Patient Pathway – New Markers and Targets – Certificate of Completion
Australie
$0
gratuit
Certificate of Completion
1 heure
Oncologie
1 Credits
Description du cours
Détails du cours
Date d'expiration : 2020-08-21
Métiers: Spécialiste
Faculté
Associate Professor Nick Pavlakis
BSc, MBBS, MMed (Clin. Epi) PhD FRACP
President, Australasian Lung Cancer Trials Group (ALTG)
President Elect, The Clinical Oncology Society of Australia (COSA)
Senior Staff Specialist, Department of Medical Oncology
Royal North Shore Hospital, NSW
Professor Ben Solomon
MBBS, PhD, FRACP
Consultant Medical Oncologist,
Group Leader, Senior Faculty Peter MacCallum Cancer Centre, VIC
Accréditation
This interactive online learning activity is valued at 1 Hour(s) of continuing education.